Amneal Pharmaceuticals, Inc.

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF: $220M normalized FCF base (blending TTM FCF of $83.11M, depressed by working-capital/capex timing, with the prior year's $241.15M); 5% annual FCF growth for years 1-5, 3% for years 6-10; 8.5% discount rate; 2.5% terminal growth; $2.66B net debt subtracted ($131.41M cash less $2.79B debt); 348.30M shares outstanding.

Reasoning: Amneal is a profitable, growing specialty/generics pharma platform, but it carries substantial leverage from its financing history, so an unlevered FCF DCF using a normalized (rather than single-year-depressed) FCF base is the most accurate method, with the heavy net debt load being the dominant factor compressing per-share intrinsic value.